Dec 18, 2013
LOUVAIN-LA-NEUVE, BELGIUM, 17 December 2013 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that the first high energy, razor sharp pencil beam of IBA’s new Proteus®ONE Compact Proton Therapy solution was produced at the Willis-Knighton Cancer Center.
The proton beam was tuned by a team of physicists and engineers led by IBA’s founder and Chief Research Officer, Yves Jongen, and reached target specifications for beam size and shape at isocenter. In the coming months, the team will fine tune these results to deliver the most precise proton therapy treatments in a compact system to Willis-Knighton Cancer Center patients.
Three Proteus®ONE compact proton therapy solutions have been ordered to date, with patient treatments expected to start in 2014. These compact centers will quickly add to the treatment capacity of the existing centers developed by IBA. To date, IBA has helped treat over 25,000 cancer patients worldwide with proton therapy.
Yves Jongen, Chief Research Officer of IBA commented: “This is a very important milestone in the development of our compact proton therapy solution. It is the talent, experience and determination of our team that makes it possible to achieve these milestones in the development of Proteus®ONE and ensures that we maintain our leading edge in innovation and our position as the world’s leader in the delivery of proton therapy.”
Lane R. Rosen, MD, Director of Radiation Oncology at WKCC, added: “IBA and Willis-Knighton Cancer Center are demonstrating once again that a strong partnership can help bring advanced cancer care to our community. We look forward to start treating patients next year on the first Proteus®ONE solution.”
Beth Klein, IBA VP Sales North America, shared: “We are very excited about how quickly the Proteus®ONE is meeting or exceeding the milestones we set for it. It will be the only compact system in the market without clinical compromise, making the highest quality proton therapy affordable for many more institutions, thereby bringing this powerful treatment to more patients.”
©
LOUVAIN-LA-NEUVE, BELGIUM, 17 December 2013 – IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that the first high energy, razor sharp pencil beam of IBA’s new Proteus®ONE Compact Proton Therapy solution was produced at the Willis-Knighton Cancer Center.
The proton beam was tuned by a team of physicists and engineers led by IBA’s founder and Chief Research Officer, Yves Jongen, and reached target specifications for beam size and shape at isocenter. In the coming months, the team will fine tune these results to deliver the most precise proton therapy treatments in a compact system to Willis-Knighton Cancer Center patients.
Three Proteus®ONE compact proton therapy solutions have been ordered to date, with patient treatments expected to start in 2014. These compact centers will quickly add to the treatment capacity of the existing centers developed by IBA. To date, IBA has helped treat over 25,000 cancer patients worldwide with proton therapy.
Yves Jongen, Chief Research Officer of IBA commented: “This is a very important milestone in the development of our compact proton therapy solution. It is the talent, experience and determination of our team that makes it possible to achieve these milestones in the development of Proteus®ONE and ensures that we maintain our leading edge in innovation and our position as the world’s leader in the delivery of proton therapy.”
Lane R. Rosen, MD, Director of Radiation Oncology at WKCC, added: “IBA and Willis-Knighton Cancer Center are demonstrating once again that a strong partnership can help bring advanced cancer care to our community. We look forward to start treating patients next year on the first Proteus®ONE solution.”
Beth Klein, IBA VP Sales North America, shared: “We are very excited about how quickly the Proteus®ONE is meeting or exceeding the milestones we set for it. It will be the only compact system in the market without clinical compromise, making the highest quality proton therapy affordable for many more institutions, thereby bringing this powerful treatment to more patients.”
©
